MK 3207Alternative Names: MK3207
Latest Information Update: 14 Sep 2009
At a glance
- Originator Merck & Co
- Class Antimigraines
- Mechanism of Action Calcitonin gene-related peptide antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 11 Sep 2009 Discontinued - Phase-II for Migraine in USA (PO)